Baidu
map

Prostate Cancer P D:一个基于国家癌症数据库的回顾分析:2004年到2013年前列腺癌IIA阶段放射疗法运用趋势情况

2017-04-13 AlexYang MedSci原创

最近的研究展现了在过去几十年中,放射疗法治疗前列腺癌的方法利用正在减少,更加保守的全面治疗方法同样存在减少趋势。最近,有研究人员对在2004年到2013年,这种减少的趋势是否持续以及各种不同放射疗法的利用的变化情况进行了研究。研究人员利用国家癌症数据库资料进行了一项回顾性研究。研究鉴定了在2003到2013年具有充足治疗信息并且被诊断为前列腺癌IIA阶段的706877名病人,并运用逻辑回归模型去评

最近的研究展现了在过去几十年中,放射疗法治疗前列腺癌的方法利用正在减少,更加保守的全面治疗方法同样存在减少趋势。最近,有研究人员对在2004年到2013年,这种减少的趋势是否持续以及各种不同放射疗法的利用的变化情况进行了研究。

研究人员利用国家癌症数据库资料进行了一项回顾性研究。研究鉴定了在2003到2013年具有充足治疗信息并且被诊断为前列腺癌IIA阶段的706877名病人,并运用逻辑回归模型去评估放射疗法利用的年度趋势。研究结果发现,从2004到2013年,与其它治疗方法比较,放射疗法的利用显着降低,从2004年的54.4%到2013年的34.5%。外离子束放射疗法(EBRT)的利用从2004年的27.1%减少到2013年的25.0%,并且短距离放射治疗从2004年的19.7%下降到2013年的6.1%。另外,组合疗法也从2004年的6.8%下降到2013年的2.6%。然而,当只考虑放射治疗这个范围时,EBRT的利用率从2004年的50.6%稳定的上升到2013年的74.0%,而短距离放射治疗从2004年的36.7%下降到2013年的18.2%。最后,尽管病人接受组合疗法在2004到2009年是降低的,但是在2009到2013年利用率有小程度的上升,即从8.3%到8.5%。

最后,研究人员指出,从2004年开始,前列腺癌治疗的放射疗法的利用率是显着降低的,包括每一种放射疗法手段。但是对病人接受用放射疗法群体中,EBRT的利用增加了,但是短距离放射疗法利用降低了。这些数据可以鼓励人们进一步研究这些趋势的原因及怎么样影响病人的治疗。

原始出处:

T Malouff, N W Mathy, S Marsh et al. Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database. Prostate Cancer P D. 11 April 2017. doi:10.1038/pcan.2017.15.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791513, encodeId=62231e91513d5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Mar 15 13:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928580, encodeId=e5cd19285808e, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Mar 09 07:00:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187732, encodeId=3cce18e732e1, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 15 22:42:28 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364161, encodeId=caeb1364161dd, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601844, encodeId=85e61601844bb, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791513, encodeId=62231e91513d5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Mar 15 13:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928580, encodeId=e5cd19285808e, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Mar 09 07:00:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187732, encodeId=3cce18e732e1, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 15 22:42:28 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364161, encodeId=caeb1364161dd, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601844, encodeId=85e61601844bb, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791513, encodeId=62231e91513d5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Mar 15 13:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928580, encodeId=e5cd19285808e, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Mar 09 07:00:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187732, encodeId=3cce18e732e1, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 15 22:42:28 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364161, encodeId=caeb1364161dd, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601844, encodeId=85e61601844bb, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
    2017-04-15 虈亣靌

    学习了很好的内容

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1791513, encodeId=62231e91513d5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Mar 15 13:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928580, encodeId=e5cd19285808e, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Mar 09 07:00:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187732, encodeId=3cce18e732e1, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 15 22:42:28 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364161, encodeId=caeb1364161dd, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601844, encodeId=85e61601844bb, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
    2017-04-14 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791513, encodeId=62231e91513d5, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Mar 15 13:00:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928580, encodeId=e5cd19285808e, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Mar 09 07:00:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187732, encodeId=3cce18e732e1, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 15 22:42:28 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364161, encodeId=caeb1364161dd, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601844, encodeId=85e61601844bb, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 14 15:00:00 CST 2017, time=2017-04-14, status=1, ipAttribution=)]
    2017-04-14 sunylz

相关资讯

J UROLOGY:二甲双胍不能增加前列腺癌的生存期

根据4月份The Journal of Urology发表的一项研究表明,二甲双胍与多西他赛联合使用并不能显着改善糖尿病伴转移性去势抵抗性前列腺癌患者的生存期。

NEJM:前列腺癌近距离放射治疗后出现肛门二重癌

前列腺癌近距离治疗后是否会发生二重癌,在学界中一直存在着争议,本文以一种个案的方式给予医生以提醒,只要有二重癌发生的风险存在,充分的告知和沟通就不应疏忽。病史回顾:Dr. Theodore S. Hong: 一名74岁有前列腺癌近距离治疗史的患者,因出现长达6个月的直肠出血而于院外诊所就诊。在6个月之前,患者状态良好,直到他发现自己大便时混有少量鲜血。在此次评估前2个月,患者大便变细。在评估的

PROSTATE CANCER P D:前列腺癌常见治疗手段与痴呆存在关联性

前列腺癌的雄激素剥夺疗法是较为常用的肿瘤治疗手段,其常见的不良反应为骨质疏松和骨折风险。而最新的研究表明,雄激素剥夺疗法与男性前列腺癌患者痴呆的发生存在某些相关性,可能的原因是雄激素对于神经元的维护作用受到影响,与阿尔茨海默病尚无定论,有待进一步研究。一项新的分析研究显示接受雄性激素剥夺疗法(ADT)治疗的前列腺癌患者与痴呆存在关联性,雄性激素剥夺疗法是一种雄激素降低治疗手段。该研究来自于宾夕法尼

Sci Rep:对高胰岛素血症可嫁接免疫缺陷小鼠模型的一些研究看法

高胰岛素血症、肥胖和血脂异常是许多癌症独立、聚合风险因素。最近,研究人员调查了适用于人体组织异体种植的两个免疫缺陷小鼠株系((NOD/SCID 和 Rag1-/-)中,23%西方高脂肪饮食(HFD)的长期影响,以及饮食诱导的高胰岛素血症对人类前列腺癌细胞系异种种植生长的影响。研究人员发现,断奶16周和23周后,Rag1-/- 和 NOD/SCID HFD喂养的小鼠表现出了在葡萄糖耐受性中饮食诱导的

Nat Commun:能够引起前列腺癌中microRNAs异常代谢的拮抗转录驱使因子的鉴定

雄激素阻断疗法是治疗转移性前列腺癌的标准疗法,但是,总会导致出现抗性现象。因此,对另外一些驱使因子的系统鉴定也许可以对有效疗法的开发提供有用的信息。很多的microRNAs对代谢具有很重要的作用,但在转移性前列腺癌症中却被异常调节了。然而,潜在的分子机制却知之甚少。最近,研究人员对转录因子(TF)和microRNAs的表达谱做了一个整体的分析,并计算鉴定了三个主效TFs,AR、HOXC6和NKX2

新方法可以有效预测肺癌,前列腺癌,乳腺癌及白血病的风险

匹兹堡大学癌症研究所(UPCI)的科学家在美国华盛顿特区的 AACR 年会上报道,保护染色体末端的 DNA 端粒长度可以预测癌症的风险并成为未来治疗的潜在靶标。

Baidu
map
Baidu
map
Baidu
map